These results have broader implications for the use of PPARG-targeting agents in obesity and metabolic disease research and provide a foundation for future studies investigating the molecular interplay between differentiation, metabolism, and cell death, potentially informing the development of novel therapeutic approaches. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.